Yannan Jia

Shanghai, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 18 publications

A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.

A randomized trial of GVHD prophylaxis in haploidentical PBSC transplantation: ATG, PTCy, and low-dose combination therapy.

Journal: Blood

Published: November 25, 2025

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

Journal: Blood

Published: September 30, 2024

Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China.

Comparison of total body irradiation (TBI) and Non-TBI conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with peripheral T cell lymphoma: a multicenter retrospective study in China.

Journal: Annals of hematology

Published: September 22, 2024

Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis.

Improved survival in older patients with myeloid malignancies undergoing haploidentical peripheral blood stem cell transplantation with low-dose anti-thymocyte globin (ATG)/post-cyclophosphamide (PTCy)-based regimen for graft-versus-host disease prophylaxis.

Journal: Annals of hematology

Published: September 15, 2024

Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China.

Application patterns and outcomes of hematopoietic stem cell transplantation in peripheral T-cell lymphoma patients: a multicenter real-world study in China.

Journal: Experimental hematology & oncology

Published: May 18, 2024

Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.

Azacitidine combined with interferon-α for pre-emptive treatment of AML/MDS after allogeneic peripheral blood stem cell transplantation: A prospective phase II study.

Journal: British journal of haematology

Published: April 05, 2024

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.

FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML.

Journal: Leukemia

Published: November 15, 2022

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.

Co-targeting BCL-XL and BCL-2 by PROTAC 753B eliminates leukemia cells and enhances efficacy of chemotherapy by targeting senescent cells.

Journal: Haematologica

Published: August 22, 2022

Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3).

Diagnostic challenge in mixed phenotype acute leukemia with T/megakaryocyte or T/myeloid lineages accompanied by t(3;3).

Journal: Diagnostic pathology

Published: August 18, 2022

Adsorption performance and optimization by response surface methodology on tetracycline using Fe-doped ZIF-8-loaded multi-walled carbon nanotubes.

Adsorption performance and optimization by response surface methodology on tetracycline using Fe-doped ZIF-8-loaded multi-walled carbon nanotubes.

Journal: Environmental science and pollution research international

Published: May 18, 2022

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.

Correction: Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia.

Journal: Signal transduction and targeted therapy

Published: April 02, 2022

Comparison of multi-omics results between patients with acute myeloid leukemia with long-term survival and healthy controls.

Comparison of multi-omics results between patients with acute myeloid leukemia with long-term survival and healthy controls.

Journal: Annals of translational medicine

Published: November 23, 2021

Showing 1-12 of 18

Last Updated: 09/26/2026